Alumis Inc. (NASDAQ:ALMS) is a clinical-stage biopharmaceutical company focusing on the development of oral therapies for immune-mediated diseases. Recently, HC Wainwright has initiated coverage on Alumis, highlighting the company’s investigational lead drug candidate, ESK-001, a Tyrosine Kinase 2 (TYK2) inhibitor. This drug is currently undergoing Phase 3 trials for moderate-to-severe plaque psoriasis and Phase 2...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
